临床试验/NCT07791199

NCT07791199尚未招募3 期

A Continuation Protocol for Deucravacitinib in Adult Patients With Systemic Lupus Erythematosus (SLE) or Sjögren's Disease (SjD) and Pediatric Patients With Psoriasis (PsO) or Psoriatic Arthritis (PsA) Who Have Completed Parent Studies

Bristol-Myers Squibb0 个研究点目标入组 2,300 人开始时间: 2026年12月31日最近更新: 2026年9月3日

适应症

干预措施

试验速览

阶段: 3 期
状态: 尚未招募
发起方: Bristol-Myers Squibb
入组人数: 2,300
主要终点: Number of participants treated

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 4 Years 至 75 Years（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Participants must have completed qualifying parent study through the protocol required treatment period. Qualifying studies include IM011-246, IM011-247, IM011-1069, IM011-126, IM011-1128, and IM011-1071.

排除标准

•Participants must not have any disease or medical condition that, in the opinion of the physician, would make them unsuitable for this protocol, would interfere with the interpretation of their safety or considered unsuitable by the physician for any other reason.
•Other protocol-defined inclusion/exclusion criteria apply.

研究组 & 干预措施

Deucravacitinib Arm

Experimental

干预措施: Deucravacitinib (Drug)

结局指标

主要结局

Number of participants treated

时间窗: Up to approximately 28 days after last dose of deucravacitinib

次要结局

未报告次要终点

研究者

发起方

Bristol-Myers Squibb

申办方类型

Industry

责任方

Sponsor

相似试验

招募中

3 期

Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s SyndromeSjogren's syndrome

2023-503327-26-00Bristol-Myers Squibb Services Unlimited Company243

招募中

2 期

DEUCRALIPLichen planus

2022-502991-21-00Rheinische Friedrich Wilhelms Universitaet Bonn30

撤回

不适用

Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory MyopathiesIdiopathic Inflammatory Myopathies (IIMs)

NCT07564271Peking University People's Hospital10

招募中

3 期

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)

CTRI/2024/11/076583Bristol Myers Squibb India Private Limited490

招募中

2 期

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety deucravacitinib in patients with chronic hand eczema (investigator-sponsored research)

2023-504298-19-00Charite Universitaetsmedizin Berlin KöR57